-+ 0.00%
-+ 0.00%
-+ 0.00%

*Zenas BioPharma: Topline Results From Pivotal Phase 3 INDIGO Trial in Immunoglobulin G4-Related Disease Expected Around Yr-end 2025 >ZBIO

Dow Jones·05/15/2025 11:07:00

Please log in to view news